<code id='854C452BB9'></code><style id='854C452BB9'></style>
    • <acronym id='854C452BB9'></acronym>
      <center id='854C452BB9'><center id='854C452BB9'><tfoot id='854C452BB9'></tfoot></center><abbr id='854C452BB9'><dir id='854C452BB9'><tfoot id='854C452BB9'></tfoot><noframes id='854C452BB9'>

    • <optgroup id='854C452BB9'><strike id='854C452BB9'><sup id='854C452BB9'></sup></strike><code id='854C452BB9'></code></optgroup>
        1. <b id='854C452BB9'><label id='854C452BB9'><select id='854C452BB9'><dt id='854C452BB9'><span id='854C452BB9'></span></dt></select></label></b><u id='854C452BB9'></u>
          <i id='854C452BB9'><strike id='854C452BB9'><tt id='854C452BB9'><pre id='854C452BB9'></pre></tt></strike></i>

          knowledge

          knowledge

          author:focus    Page View:19
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          More tobacco lobbyists active in statehouses
          More tobacco lobbyists active in statehouses

          NathanHoward/GettyImagesWASHINGTON—Aroundthecountry,statehousesfromHarrisburg,Pa.,toTallahassee,Fla.

          read more
          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more

          STAT Summit: Michael J. Fox on progress in Parkinson's research

          STATWhenMichaelJ.FoxwasdiagnosedwithParkinson’sdiseaseatage29,hisclearestsymptomwasasmallone—hispink